A Phase 3 interventional study of Tranexamic Acid Injectable Solution and Placebo in Hip Fractures, sponsored by Lancaster General Hospital. Completed at 1 site in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2024-10-10.
Sponsored by Lancaster General Hospital · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing Tranexamic Acid in Hip Fractures — 2 open to participants now, 3 under way, none of them phase 3. Tranexamic Acid · Hip Fractures.
Among the 22 studies testing Tranexamic Acid in Hip Fractures, this one is the 2nd largest by enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2020, is one of 4 in phase 3, and was the 17th registered.
843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.
Browse Hip Fractures studies →2 of the 22 studies testing Tranexamic Acid in Hip Fractures are open now, in 2 countries. Recruiting first, the newest first:
University Hospital for Surgical Diseases St. Naum Ohridsk i- Skopje · Sites in North Macedonia
Ages 65+
Biogipuzkoa Health Research Institute · Sites in Spain
Ages 65+
By country, each count listing its studies:
Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →
Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 283 is above the median of 86 across 534 interventional studies indexed under Hip Fractures.
Median enrollment 120 across the 21 interventional studies. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 22 has an industry lead sponsor. The 10 most frequent:
Lancaster General Hospital is the lead sponsor of 21 studies on the registry; 3 are open to participants now.
Lancaster General Hospital has 2 studies filed under Hip Fractures — fewer than ten, so there is no comparison to draw.
2 of the studies testing Tranexamic Acid in Hip Fractures that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07432737University Hospital for Surgical Diseases St. Naum Ohridsk i- SkopjeOne Versus Two Doses of Tranexamic Acid in Surgically Treated Extracapsular Hip Fractures | 2027-05 |
| NCT03063892Gregory M Georgiadis MDEffect of Tranexamic Acid (TXA) on Reduction of Postoperative Blood Transfusion | 2027-07-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies testing Tranexamic Acid in Hip Fractures, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The overall design of the study is a prospective, double-blinded, randomized study in the geriatric hip fracture population comparing those who receive intravenous tranexamic acid prior to incision to those who receive a placebo.
A significant portion of the geriatric hip fracture population have comorbidities including chronic kidney disease, congestive heart failure, ischemic heart disease, stroke, etc. These patients may be anemic prior to the surgery, and are at increased risk for further blood loss as a result of the fracture and surgical operation. However, intra-operative or post-operative blood transfusions also increase the risk of renal and cardiac complications in this population.
Tranexamic acid (TXA) is an anti-fibrinolytic medication that has transformed total joint replacement management regarding blood loss prevention. Geriatric patients requiring emergent hip fracture repair may significantly benefit from routine administration of TXA prior to the procedure to decrease the risk of blood loss. Thus, treatment may further reduce the percentage of patients who experience blood transfusions and complications associated with transfusions.
The investigators will examine if administration of TXA prior to incision in the geriatric hip fracture patient population decreases the risk of intra-operative or post-operative blood transfusions compared to placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
100 cc normal saline with 1g of tranexamic acid in solution
Drug: Tranexamic Acid Injectable Solution
100 cc normal saline
Other: Placebo
100 cc normal saline mixed with 1g of tranexamic acid in solution
Also known as: Cyklokapron
100 cc normal saline
Count of Participants With Acute Post-operative Transfusion of Packed Red Blood Cells.
Count of participants with acute post-operative transfusion of packed red blood cells along with the corresponding 95% CI.
Time frame: 3 Months
Complication Rate
Determine if participants randomized to TXA experienced increased risk of complications compared to placebo. Complications include number of deep vein thrombosis events, pulmonary emboli events, myocardial infarction events, and cerebral vascular events within 12 weeks post hip fracture surgery.
Time frame: 3 Months
Hospital Readmission
Determine differences between the groups in 30 day readmission rates.
Time frame: 30 Days
Mortality Rate
Death within 90 days post hip surgery
Time frame: 90 Days
Length of Stay
Length of stay immediately post study intervention/surgery for hip fracture
Time frame: From date of study intervention/surgery for hip fracture until the date of discharge or date of death from any cause, whichever came first, assessed up to 34 months.
| Milestone | Intervention | Placebo |
|---|---|---|
| Started | 146 | 138 |
| Completed | 73 | 68 |
| Not completed | 73 | 70 |
| Withdrew: Death | 16 | 12 |
| Withdrew: Lost to follow-up | 56 | 56 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Participant enrolled twice for separate hip fractures - one enrollment removed. | 0 | 1 |
Count of participants with acute post-operative transfusion of packed red blood cells along with the corresponding 95% CI.
| Participants | Intervention | Placebo |
|---|---|---|
| Count of Participants With Acute Post-operative Transfusion of Packed Red Blood Cells. | 118 | 111 |
Determine if participants randomized to TXA experienced increased risk of complications compared to placebo. Complications include number of deep vein thrombosis events, pulmonary emboli events, myocardial infarction events, and cerebral vascular events within 12 weeks post hip fracture surgery.
| Participants | Intervention | Placebo |
|---|---|---|
| Complication Rate | 43 | 30 |
Determine differences between the groups in 30 day readmission rates.
| Participants | Intervention | Placebo |
|---|---|---|
| Hospital Readmission | 11 | 8 |
Death within 90 days post hip surgery
| Participants | Intervention | Placebo |
|---|---|---|
| Mortality Rate | 15 | 11 |
Length of stay immediately post study intervention/surgery for hip fracture
| days | Treatment | Placebo |
|---|---|---|
| Length of Stay | 5 ± 4.1 | 4.8 ± 3.8 |
Collected over 3 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Intervention | 16/146 (11%) | 3/146 (2.1%) | 69/146 (47.3%) |
| Placebo | 12/137 (8.8%) | 1/137 (0.7%) | 57/137 (41.6%) |
| Event | Intervention | Placebo |
|---|---|---|
| DeathGeneral disorders | 0/146 | 1/137 |
| Hyperglycemia (worsening of condition -> death)Endocrine disorders | 1/146 | 0/137 |
| Acute infarct in R parietal region (pt released on hospice)Vascular disorders | 1/146 | 0/137 |
| Post-operative respiratory failure with hypercarbiaRespiratory, thoracic and mediastinal disorders | 1/146 | 0/137 |
| Event | Intervention | Placebo |
|---|---|---|
| MildGeneral disorders | 44/146 | 38/137 |
| ModerateGeneral disorders | 25/146 | 19/137 |
Participant enrolled twice for separate hip fractures - one enrollment removed.
| Age, Continuous(years) | Intervention | Placebo | Total |
|---|---|---|---|
| Mean | 88.2 ± 11 | 86.0 ± 8.7 | 87.2 ± 13 |
| Sex: Female, Male(Participants) | Intervention | Placebo | Total |
|---|---|---|---|
| Female | 105 | 106 | 211 |
| Male | 41 | 31 | 72 |
| Ethnicity (NIH/OMB)(Participants) | Intervention | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 1 | 3 |
| Not Hispanic or Latino | 144 | 136 | 280 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Intervention | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 142 | 134 | 276 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 3 | 7 |
| Region of Enrollment(participants) | Intervention | Placebo | Total |
|---|---|---|---|
| United States | 146 | 137 | 283 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2020 to primary completion in Dec 2022, 34 months.
Results were first posted in Oct 2024, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tranexamic Acid
Lancaster General Hospital